FR2670416: A synthetic peptide formulation against melanoma and other cancers over-expressing S100B
The invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.
Patent No:
FR2670416
Application No:
12710321
Filing Date:
30-07-2013
Issue Date:
30-11-2016
Applicant:
CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata
Inventor(s):
Amlanjyoti Dhar, Shampa Mallick, Israr Ahmed, Aditya Konar, Santu Bandyopadhyay, Siddhartha Roy
IPC Classification:
A61K38/00, C07K14/00,
Country:
France
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Accessibility Controls